Last reviewed · How we verify

NCT04050488

Zinc Supplementation on Very Low Birth Weight Infant

Status unknown Phase 4 Last updated 15 August 2019
What this trial tests

Phase 4 trial testing Zinc Sulfate in Early-Onset Sepses, Neonatal in 364 participants. Status unknown.

Timeline
20 August 2019
Primary endpoint
31 July 2020
31 July 2020

Quick facts

Lead sponsorFakultas Kedokteran Universitas Indonesia
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment364
Start date20 August 2019
Primary completion31 July 2020
Estimated completion31 July 2020

Drugs / interventions tested

Conditions studied

Sponsor

Fakultas Kedokteran Universitas Indonesia — full company profile →

Who can join

Under 3 Days, any sex, with Early-Onset Sepses, Neonatal or Periventricular Haemorrhage Neonatal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Premature birth is a major cause of neonatal death in addition to neonatal asphyxia and infections. Early in life, premature babies must get aggressive nutrition so that there is no extrauterine growth restriction (EUGR) in the Intrauterine Growth Restriction (IUGR) group compared to the non-IUGR group. Other factors that also play a role are long episodes of fasting, the fulfillment of nutrition (macro and micronutrients) from the start, time to start breastfeeding (ASI), duration of parenteral total administration, the incidence of respiratory distress syndrome and incidence of necrotizing enterocolitis. Zinc is one of the micronutrients which is very risky for deficiency in premature babies. Babies with zinc deficiency experience growth disorders as much as 67%. In India, infants who received zinc supplementation increased after being given 10 days of zinc supplementation and lower mortality rates in the group with supplementation. Very low birth weight babies and bronchopulmonary dysplasia who received zinc supplementation during the week showed good clinical progress and the growth rate also increased. The investigators believe this study has the potential for decreasing infant mortality from its current level and can be a growth indicator for preterm babies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Enteral zinc supplementation for prevention of morbidity and mortality in preterm neonates.
    Staub E, Evers K, Askie LM. · · 2021 · cited 25× · PMID 33710626 · DOI 10.1002/14651858.cd012797.pub2
  2. Enteral Bioactive Factor Supplementation in Preterm Infants: A Systematic Review.
    Mank E, Naninck EFG, Limpens J, van Toledo L, et al · · 2020 · cited 7× · PMID 32987621 · DOI 10.3390/nu12102916

Verify or expand the search:

Other trials of Zinc Sulfate

Trials testing the same drug.

Other Fakultas Kedokteran Universitas Indonesia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04050488.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing